Bob Bradway, Amgen CEO
#ESMO22: Amgen drops the detailed deck for KRAS G12C, with eroding data likely to trigger fresh debate
PARIS — Amgen put its best foot forward in Paris early Monday, with the news that its KRAS G12C star Lumakras offered a solid benefit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
